Member Info for Almostrich

So I had the audacity to mention liposomal doxorubicin. Oh dear! Avacta did so too, pointing out there is considerable scope for improvement.

Currently there are academic groups and company research labs across the world pursuing what for them is also the holy grail. A safe and effective way of delivering dox to a tumour. All sorts of ingenious methods are being attempted, use of nano particles being a favourite option. A large amount of time, effort and money has already been spent by these groups. Why? because it’s just as Avacta stated “there is huge potential for an improved next generation dox product”.

So then, when Avacta publish their p1a data can you imagine what the impact is going to be for all these other groups spread across the world. Avacta raising the bar so high it will send out the most almighty shockwave that will reverberate through all those groups. It will seriously affect their choices when it comes to deciding whether to push on into preclinical etc! It will stop some in their tracks by posing serious questions. P1b then P2 results will add further pressure. That’s the point, it will kill off some of the potential competition before it even gets motoring. It will certainly cause some to think about diverting their unique delivery mechanism towards drugs other than dox.

The impact of Avacta’s technology will be felt far and wide. Crazy to think some people tried to mock Avacta when the White City advertisement led with the word “revolutionising”. It definitely was not an exaggeration!

Don’t understand ask bein😀

Groot, if you’ve followed the story you will have noticed frequent reference to the Pk data, when will it be published etc, etc. All I’ve done is raise its profile because it is as important to the commercialisation of the pre|CISION™ platform as the clamour for biopsy and efficacy data etc is for AVA6000. Nothing more, nothing less.

For sure don’t look at figure 7, it was nothing more than a simple illustration, your correct liposomal doxorubicin is pretty crap and the well researched already knew that. Avacta are creating their own (obviously!) powerful PKPD model for the pre|CISION™ platform. The more astute here already knew that too! And the fact that the model is key and links to the price pharma will have to pay, of course!

Sorry tim**** you’re going to have to write another post!

Https://www.frontiersin.org/articles/10.3389/fphar.2020.00997/full

See Figure 7

For those who really still don’t get the message, this is what pharma will be paying for when they buy the pre|CISION™ platform, a more highly developed version of course.

PL you’re such a paradox, clever and articulate but dumb at the same time.LOL

My job here is done for now!

Look under the bonnet peoples!

No, it was releasing to a party interested in the pre|CISION™ platform versus releasing to the scientific community via a publication.

If the content doesn’t interest you stick it in your dribble bin.

When pharma take their licence into the lab to develop the pre|CISION™ form of one of their own toxic drugs what is it they will have that caused them to part with their cash. Their science guys will have gone through the data and validated it but at its core there must be something that caused the decision makers to open the purse. They always need to be convinced. They may agree the science is revolutionary but how do they know it will work for them? In what way is it at least partially de-risked?

In my simple view it’s about a thread of confidence and validity that runs through the data and started way back when they embarked on the pre-clinical rodent studies. The pre-clinical created a model for rodents. They moved onto humans using that model as a starting point. With human trial data from p1a they’ve tested and refined that model. Further still that model is now going to inform the start of p1b see AGM, page 16, “Use PK/PD modelling to identify safe and effective dose from preclinical and emerging clinical data”. No doubt data from p1b will be used to further test and refine this model going forwards.

If that initial preclinical model proved itself to be highly accurate when translating to human data (it doesn’t always I believe) and has improved predictability from then on, then it must tell pharma an awful lot about pre|CISION™

Or in other words it gives some validity to the assumption that pharma’s own preclinical work will also likely relate closely to optimum conditions in humans when they head into human clinical trials. Ba-Boom! There you have one very important element of de-risking that they’ll be looking for.

Personally I don’t think pharma will see p1a Pk data until it finishes. The level of accuracy, predictability, or whatever that Avacta see are clearly sufficient for them to start commercialisation of the platform post 1a.

Too right, the answer is so obvious!

As soon as it starts! Not trying to be facetious here. Avacta running down two tracks. Firstly taking AVA6000 through to commercialisation for which the data relating to dox, biopsies and anything related to efficacy is what we all really want to see as soon as possible after p1b starts. I’ve no idea when that will be.

Secondly, do deal on the pre|CISION™ platform for another BP drug for which the the p1b data etc is important and rolls in right from from day 1. When will p1b start? Again no idea.

Not much help I know!

Trial data constantly rolling in and every single bit of it chipping away at whatever risk factors remain for BP. Risk coming down all the time. Zero risk by end P1a?

Or would they need to see data from P1b? However, as risk comes down price goes up. Avacta doing hard bargaining here I suspect. Reckon BP have filled the pen with ink but when will they sign?

Well the sooner the better obviously. Once BP realise pre|CISION™ is a bargain GPS guaranteed to find the tumour rather than a map plus ask a friend they’ll do the business.

Good morning to the weekend keyboard thugs. You’re all such pleasant characters.

Hope you all have a good week. 😀

When theses companies do come knocking at Avacta’s door they’ll want to know all about the pre|CISION™ platform rather than dox. Levels of dox in the tumour will impress them, further data that tells them about the pre|CISION™ platform lies under the bonnet. Some nice surprises under there I’m sure.

Gje anything I say will do nothing other than provoke further attack so pointless. If it comes from the mouth of AS, FM or others through what they say in future q&a and interview it will be obvious to all whether there were any surprises or not.

They’re on DE6 it’s a suprise, safety profile “remarkable”

“Someone or something that is remarkable is unusual or special in a way that makes people notice them and be surprised or impressed.”

I don’t need to be subtle

All the ONCO stuff relating to therapy is still preclinical.

Imaging stuff is in phase 1

https://www.philochem.ch/pipeline/

Long way back in Avacta’s rear view mirror

Gje not going to bother with this anymore. I think the answer to your question will emerge over time.

No concerns here, I’m happy with the ground I covered

Competition: yes but currently behind ✅

STS: Will reveal AVA6000 strengths (FAP variability vs AVA6000 consistency)✅

FAP/ preCision now in the limelight✅

Made aware of threads app. Thank you PL✅

A few shareholders may have looked at the referenced info✅

Please don’t hold your breath waiting for a deramp wouldn’t want Avacta to lose any of its important shareholders!

Yeh, but with a very good understanding of what’s going down at Avacta.

Be grateful if someone other than me can report and get this thread deleted, it’s run its course!

Sorry no can do!

But II sincerely apologise if my use of the term “Scandi” offended anybody reading my posts it seemed the most apt word at the time.

I was reading pharma’s tweets in real time as they appeared. For those that didn’t see, he posted 10, 15 maybe even more individual tweets in rapid succession over a period minutes. Some contained barely a few words. He deliberately broke it all up. Could easily of sent single tweet. Perhaps I should have described it as minimal, simple and deliberately broken up English. Oh well, we live and learn!

Profound apologies to the apostrophe policeman (or is it men)

I’ll finish contributing to this thread with my very crude analogy

Avacta turned up at the firing range with a new weapon in their box. Something between a shotgun and a basic rifle. Confident they would hit the target but nervous of a bit of spread. Started firing and were taken aback, realised the weapon they had was so much more powerful. A few more shots away and the results were telling them they had something really special, more akin to a laser focused hunting rifle. Wow! That’s great but hold on a minute, we have to learn how to us the bloody thing properly if we’re going to be able to demonstrate it to customers. Well that’s ok we can run it in auto-mode initially and while that’s going on we can work through how to use it manually in different situations, bit like a camera.

Meanwhile at the firing range shareholders without binoculars can’t see the targets but they know from people’s reactions the results must be incredibly good.

Avacta are reacting in real time as the trial data comes in. Whilst it’s easy to get impatient as Avacta look to determine MTD they are also accruing valuable info about the entire dose-toxicity relationship which has got to be important in the longer run (at some point in the future may need to consider different dosage regimens and ranges of doses for whatever reason eg tailored to individual patient). Having recovered from initial shock Avacta putting in place a strategy to best ensure that the wider potential that they now see can be exploited. In my opinion few outside of Avacta really know the full extent of what’s under the bonnet here but AVA6000 does what it says on the tin, preCision!

Haven’t checked for spelling, grammar, punctuation and all that stuff so again apologies if you find errors.

PL, as I’ve said been around here a good while and until Musk decided he wanted to kill Twitter I was able to follow stuff on there without needing a sign-in. Saw pharma pop up and he caught my attention despite the very scandi English I thought worth reading etc couldn’t believe the about turn, the English magically improved, still broken and then he flipped also then turning up on the LSE board with even better English. It was such an elaborate attempt to undermine Avacta so I had a quick dig around and decided to post what I found re competition. While I was here I thought I would have a crack at the penguin. As absurd as it seems to me I just can’t shake the idea he’s paid to to do what he does perpetuate conversations by any means.

The simplest answer is usually the correct one. Isn’t that what you say?

I’m cool thanks. Others seem to be flapping like butterflies, reckon you all must have queasy stomach’s.